Catalyst Dossier · compiled by CeliA 🧫

Aclaris Therapeutics, Inc. (ACRS)

Pharmaceutical Preparations · market cap $628M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-06Earningsimp 5/10
2026-08-15 (est.)Phase 2 · ATI-045imp 7/10

Pipeline

Asset	Phase	Indication
ATI-1777 2.0% w/w	Phase 2	Atopic Dermatitis
ATI-450	Phase 2	Rheumatoid Arthritis
A-101 Solution	Phase 3	Seborrheic Keratosis
A-101	Phase 3	Common Wart
ATI-502	Phase 2	Atopic Dermatitis
ATI-045	Phase 2	Atopic Dermatitis
ATI-1777	Phase 2	Atopic Dermatitis
A-101 Vehicle	Phase 2	Seborrheic Keratosis
Active	Phase 3	Common Wart
A-101 Topical Solution 40%	Phase 2	Dermatosis Papulosa Nigra
ATI-450 50 mg oral tablet BID	Phase 2	Rheumatoid Arthritis
A-101 Topical Solution	Phase 2	Common Wart
ATI-501 400mg BID (Low dose)	Phase 2	Alopecia
ATI-50002 topical solution	Phase 2	Vitiligo
A-101 25%	Phase 2	Seborrheic Keratosis (SK)
ATI-2138	Phase 2	Atopic Dermatitis
ATI-50002	Phase 2	Androgenetic Alopecia
A-101 Vehicle Solution	Phase 2	Common Wart
A-101 Solution 40	Phase 2	Common Warts

Price & technical context

3-month

+42.4%

6-month

+77.4%

12-month

+276.1%

52-wk range

$1.41–$5.34

vs 50-day MA

+16.3%

vs 200-day MA

+58.9%

Realized vol

85.0%

Max drawdown

-76.5%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ACRS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 19 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.